Meister
- Mailadresse: Elisabeth Meister, MD
- Datum + Kategorie: Clinician Scientist
Laboratory for Pediatric Nephrology Research
— Dr. med. Anne Mühlig
Our research group investigates the molecular mechanisms underlying the development and progression of pediatric kidney diseases. A particular focus lies on sex-specific differences and the identification and characterization of differentially regulated pathways.We are especially interested in the role of the immune system and its sex-specific regulation in disease processes. To address these questions, we combine established mouse models and cell culture systems with state-of-the-art omics technologies and standardized molecular biological methods. Our goal is to uncover novel molecular mechanisms and translate these findings into druggable targets, ultimately enabling the development of individualized therapies for children with kidney diseases.
Junior Group Leader
Department of Pediatrics, University Medical Center Hamburg-Eppendorf (UKE)
Martinistr. 52
20246 Hamburg, Germany
| since 2025 |
Principal Investigator in CRC/TR 422 Project A4 |
| since 2024 |
Principal Investigator in CRC1192 Project B8 |
| since 2011 | Physician, Department of Pediatrics, University Medical Center Hamburg- Eppendorf |
|
2001 - 2007
|
Study of Medicine, Medical University Innsbruck, Austria |
|
20152020
|
Board Certification for Pediatrics |
|
20152020 |
PhD-Thesis: Department of Pediatrics, University Medical Center Hamburg-Eppendorf, Germany |
|
2007
|
MD Thesis: Department of Pediatrics, Medical University Innsbruck, Austria |
Clinical postgraduate education:
| 2011 - 2015 |
Attending Physician for Pediatrics, University Medical Center Hamburg- Eppendorf, Germany |
|
2007 - 2011
|
Attending Physician for Pediatrics, Medical University Innsbruck, Austria |
|
2024 - 2020
|
Grundlagen-Forschungspreis der Gesellschaft für Pädiatrische Nephrologie |
| 2023 |
Dr. Martini Preis, University Medical Center Hamburg-Eppendorf |
| 1. |
Mühlig AK, Hengel FE, Oh J, Tomas NM, Huber TB. Pediatr Nephrol. 2026 Apr 23. doi: 10.1007/s00467-026-07292-9. |
| 2. | Liaukouskaya N, Hengel FE, Mühlig A, Tomas NM, Huber TB. Clin J Am Soc Nephrol. 2026 Jan 21. doi: 10.2215/CJN.0000001008.
|
| 3. |
Bruno V, Mühlig AK, Oh J, Licht C. Mol Cell Pediatr. 2023 Apr 15;10(1):3. |
| 4. |
Hengel FE, Chong MCZ, Leung WY, Dehde S, Mühlig A, Janneck M, Wu HHL, Huber TB, Ponnusamy A, Tomas NM. Kidney Int Rep. 2025 May 12;10(8):2800-2804. |
| 5. |
Gies SE, Hänzelmann S, Kylies D, Lassé M, Lagies S, Hausmann F, Khatri R, Zolotarev N, Poets M, Zhang T, Demir F, Billing AM, Quaas J, Meister E, Engesser J, Mühlig AK, Lu S, Liu S, Chilla S, Edenhofer I, Czogalla J, Braun F, Kammerer B, Puelles VG, Bonn S, Rinschen MM, Lindenmeyer M, Huber TB. Am J Physiol Renal Physiol. 2024 Nov 1;327(5):F822-F844. |
| 6. |
Braun F, Abed A, Sellung D, Rogg M, Woidy M, Eikrem O, Wanner N, Gambardella J, Laufer SD, Haas F, Wong MN, Dumoulin B, Rischke P, Mühlig AK, Sachs W, von Cossel K, Schulz K, Muschol N, Gersting SW, Muntau AC, Kretz O, Hahn O, Rinschen MM, Mauer M, Bork T, Grahammer F, Liang W, Eierhoff T, Römer W, Hansen A, Meyer-Schwesinger C, Iaccarino G, Tøndel C, Marti HP, Najafian B, Puelles VG, Schell C, Huber TB. J Clin Invest. 2023 Apr 4:e157782. |
| 7. |
Mühlig AK, Oh J, Huber TB. Kidney Int. 2023 Mar;103(3):464-466. |
| 8. |
Mühlig AK, Steingröver J, Heidelbach HS, Wingerath M, Sachs W, Hermans-Borgmeyer I, Meyer-Schwesinger C, Choi HY, Lim BJ, Patry C, Hoffmann GF, Endlich N, Bracke K, Weiß M, Guse AH, Lassé M, Rinschen M, Braun F, Huber TB, Puelles VG, Schmitt CP, Oh J. Kidney Int. 2022 Mar 7:S0085-2538(22)00175-2. |
| 9. | Podocytes Produce and Secrete Functional Complement C3 and Complement Factor H. |
| 10. |
Mühlig AK, Lee JY, Kemper MJ, Kronbichler A, Yang JW, Lee JM, Shin JI, Oh J. J Clin Med. 2019 Jun 16;8(6):860. |
Research Group for Epidemiology and Clinical Nephrology
“Understanding the epidemiology and complex burden of progressive kidney disease”
— Dr. med. Christian Schmidt-Lauber
Kidney diseases pose a significant challenge to global health, explained by the high prevalence and the debilitating consequences on various other organs associated with chronic kidney disease (CKD). However, understanding is evolving that acute kidney injury (AKI), which has conventionally been seen as a transient occurrence, also significantly contributes to long-standing adverse effects on multiple organs, progression of CKD, and the increased long-term mortality. As such, AKI aligns with traditional risk factors for progressive kidney disease, such as hypertension and diabetes. These somatic risk factors are accompanied by demographic and socioeconomic determinants as well as an increasing set of medical treatments influencing kidney diseases or their risk factors.
Our group aims to better understand this complex web of disease modifiers within the trajectory of kidney diseases, their consequences, as well as hypertension, as one of the major somatic risk factors. Additionally, we try to elucidate the underlying role of inflammation, which is emerging as a major pathophysiological component within the kidney disease trajectory. Our work includes a broad set of epidemiological strategies and methods and is performed on large population-based studies (Hamburg City Health Study), AKI and CKD cohort studies (Hamburg and European Renal Omics Bank), as well as overarching nationwide German and Danish registries. This undertaking is conducted with the support of national and international collaborating partners.
Junior Group Leader
III. Department of Medicine, University Medical Center Hamburg-Eppendorf (UKE)
Martinistr. 52
20246 Hamburg, Germany
|
since 2024 |
Managing attending, III. Department of Medicine, University Medical Center Hamburg-Eppendorf |
|
since 2024
|
Junior group leader supported by the BMBF iSTAR Advanced Clinician Scientist program |
| since 2023 |
Spokesperson of the Research Alliance of the Hamburg City Health Study |
| since 2022 |
Attending physician, III. Department of Medicine, University Medical Center Hamburg- Eppendorf, Germany |
|
2007- 2014
|
Medical School, University Münster, Germany |
| 2014 |
Practical training University of California Medical School, Department of Medicine, San Diego, USA |
| 2025 |
Habilitation at the University of Hamburg |
|
2025 |
Board Certification in Internal Medicine |
|
2021 - 2020
|
Board Certification in Nephrology and Internal Medicine |
|
2021
|
Certification as expert in hypertension (DHL®) |
|
2019
|
Board Certification in Emergency Medicine |
|
2013
|
Dissertation as Doctor of Medicine, University Münster, Germany (summa cum laude) |
Clinical postgraduate education:
|
2019 - 2021
|
Residency in Nephrology and Internal Medicine, III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Germany |
| 2016 |
Visiting Clinician, Department of Nephrology, Yale University, New Haven,USA |
|
2015 - 2019
|
Residency in Nephrology and Internal Medicine, Department of Nephrology and Hypertension, Friedrich-Alexander-University Erlangen-Nürmberg, Germany |
Scientific education:
|
2012 - 2015
|
Research Fellow, Division of Experimental Nephrology, Department of Internal Medicine D, and Institute of Musculoskeletal Medicine, University Hospital Münster, Germany |
|
2011 - 2012
|
Research Fellow, Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, USA |
|
2024 - 2020
|
Dr.-Günther-Sawitzki-Award of the German Society for Hypertension (DHL®) |
|
2023
|
Best Poster Award, German Society of Transplantation (DTG) |
|
2022
|
“Teacher of the year” Award, University Medical Center Hamburg-Eppendorf, Germany |
|
2015
|
Award for the best Medical Thesis, University of Münster, Germany |
| 1. | Prevalence and Characteristics of Chronic Kidney Disease in the Hamburg City Health Study. |
| 2. | Kidney Function and Cerebral Small Vessel Disease. |
| 3. | Acute kidney injury predicts mortality in very elderly critically-ill patients. |
| 4. | Kidney outcome after mild to moderate COVID-19. |
| 5. | Molecular consequences of SARS-CoV-2 liver tropism. |
| 6. | Increased rejection rates in kidney transplantations during the COVID-19 pandemic. |
| 7. | Gadolinium-based compounds induce NLRP3-dependent IL-1β production and peritoneal inflammation. |